Odyssey
  • Homepage
  • Objectives
  • News
  • Publications
  • Privacy
    • Privacy Policy
    • Cookie Policy
  • Contact
  • Restricted
Select Page

Pharmacokinetics of dolutegravir 5mg dispersible tablets in children weighing 6 to <20kg dosed using WHO weight bands

by odysseyadmin | Jan 24, 2020 | Publication

Authors: Waalewijn H, Bollen PDJ, Moore C, Kekitiinwa A, et al. The ODYSSEY Trail Team
Published in: Oral Presentation at 10th IAS Conference, July, 21-24th 2019


Download

Recent Posts

  • EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir
  • Cheaper HIV treatment for children: a report in the Lancet
  • European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV
  • ODYSSEY trial data published in Lancet – shows increase in treatment options for older children living with HIV
  • Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

Recent Comments

    Archives

    • January 2021
    • December 2020
    • November 2020
    • August 2020
    • June 2020
    • May 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • March 2019
    • July 2018
    • June 2018
    • April 2018
    • August 2017
    • September 2016

    Categories

    • ODYSSEY
    • Publication

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    This study is funded by ViiV Healthcare and the sponsor is PENTA Foundation